Imatinib in Dermatofibrosarcoma Protuberans (DFSP)

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether imatinib is effective in the treatment of primary and recurrent dermatofibrosarcoma protuberans (DFSP).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dermatologic Cooperative Oncology Group
• Treatments: Imatinib Mesylate

Criteria

Inclusion Criteria:

• Histological diagnosis of primary or recurrent dermatofibrosarcoma protuberans

• Measurable tumor parameters (by magnetic resonance imaging [MRI])

• Patient >/= 18 years of age

• ECOG performance status < 3

• Adequate organ function

• Patients must be able to swallow capsules

• Female patients of childbearing potential must have negative pregnancy test

• Written, voluntary, informed consent; must include investigational use of tumor tissue biopsies.

Exclusion Criteria:

• Any evidence of distant metastases

• Patient has received any other investigational agents within 28 days of first day of study drug dosing

• Patient is < 5 years free of another primary malignancy except basal cell skin cancer or cervical carcinoma in situ

• Grade III/IV cardiac problems as defined by the New York Heart Association

• Severe and/or uncontrolled medical disease

• Known diagnosis of human immunodeficiency virus (HIV) infection